President Donald Trump has announced that all generic drugs imported into the United States would co

Wall Street analysts upgraded Fortinet, Goldman Sachs, Adaptive Biotechnologies, and Five Below, wit

Top Wall Street analysts change outlook on top stocks. For analyst rating changes, see https://www.b

AXSM advances AXS-12 toward potential approval after the FDA accepts its NDA for cataplexy in narcol

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Axsome Therapeutics (NASDAQ:AXSM) w

Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatm

FDA sets PDUFA target action date of May 1, 2027 NEW YORK, July 15, 2026 (GLOBE NEWSWIRE) -- Axsome

NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceu

These three biotechs are posting strong revenue growth. Brand-new launches and label expansions shou

Axsome has a solid late-stage pipeline and growing commercialized drugs. Revolution aims to revoluti

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

AXSM doses the first patient in the phase III FOCUS-2 study of solriamfetol for treating ADHD in chi

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Axsome Therapeutics (NASDAQ:AXSM) w

RBC Capital analyst Leonid Timashev maintains Axsome Therapeutics (NASDAQ:AXSM) with a Outperform

FOCUS-2 (Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol) is a Phase 3,

The FOCUS-2 trial in children complements the recently announced FOCUS-3 trial in adolescents with A

Each of these biotech players has reached an important turning point. Recent drug approvals could su

Axsome specializes in central nervous system disorders, including depression, migraine, and fibromya

In this week's edition of InnovationRx, we look at Axsome's growing pipeline, HistoSonics innovative

Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatm

NEW YORK, June 26, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceu

NEW YORK, June 18, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceu

All three could become highly prominent biotech companies within 10 years.

NEW YORK, June 15, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceu

Axsome Therapeutics, Inc. (AXSM) Presents at Goldman Sachs 47th Annual Global Healthcare Conference

Axsome Therapeutics NASDAQ: AXSM executives said the company is preparing to launch Auvelity in Alzh

NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceu

Axsome (AXSM) reported earnings 30 days ago. What's next for the stock?

NEW YORK, June 03, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a bio

Health officials explored restricting specific antidepressants among SSRI drugs-sources

Global Business Travel Group Inc (GBTG), a NYSE-listed company, saw its stock rise 57% on Monday af

Axsome gains after securing global rights to balipodect from Takeda, advancing schizophrenia pipelin

PPL Corporation (NYSE:PPL) announced it plans to sell 20,000,000 equity units in a public offering.

Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earn

Stocks That Hit 52-Week Highs On Tuesday